Linked Life Data

12831345

Source:http://linkedlifedata.com/resource/pubmed/id/12831345

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2003-6-30
pubmed:abstractText
Rheumatoid arthritis is a chronic autoimmune disease characterised by inflammation of the synovial lining of joints and destruction of cartilage and bone. Many pro-inflammatory cytokines, chemokines and growth factors are expressed in diseased joints, and recognition of the key role of TNF-alpha led to the development of highly effective new therapies. TNF-alpha inhibitors, such as monoclonal anti-TNF-alpha antibody infliximab (Remicade), have demonstrated efficacy in clinical trials. It is now clear that TNF-alpha blockade, in addition to reducing joint inflammation and leukocyte infiltration, also results in decreased formation of new blood vessels in the synovium. Such mechanism of action studies are now paving the way for the development of the next generation of drugs for treatment of rheumatoid arthritis.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1354-3784
pubmed:author
pubmed:issnType
Print
pubmed:volume
12
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1087-95
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
2003
pubmed:articleTitle
The therapeutic potential of TNF-alpha blockade in rheumatoid arthritis.
pubmed:affiliation
Kennedy Institute of Rheumatology, Faculty of Medicine, Imperial College, United Kingdom. e.paleolog@imperial.ac.uk
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't